Neurodegeneration and gliosis are prominent pathological features of subjects with human immunodeficiency virus (HIV) dementia complex (HAD). In these patients, neurodegeneration occurs in uninfected neurons. In addition, these patients develop sensory neuropathy despite the antiretroviral therapy. The HIV protein gp120, which mimics some of the pathological alterations seen in HAD, is retrogradely transported in rodent neurons. However, it is still unclear whether gp120 can also be transported anterogradely and whether axonal transport can occur in the peripheral nervous system (PNS). To determine whether gp120 is transported retrogradely and/or anterogradely, we injected gp120IIIB together with the retrograde tracer fluoro-ruby (FR) or the anterograde tracer 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyamine perchlorate (DiI) into the rat superior colliculi. We discovered that gp120 is retrogradely transported with FR along a direct pathway from the superior colliculus to the retina and anterogradely transported with DiI to several areas of the occipital cortex. To determine whether gp120 is also axonally transported in the peripheral nerves, gp120 and FR were injected into the sciatic nerve. No gp120 immunoreactivity was found in the sciatic nerve or dorsal root ganglia, suggesting that gp120 axonal transport does not occur in the PNS. Gp120 axonal transport may play a role in neuronal injury. Therefore, we examined apoptosis at various time points after gp120 injection. Activated caspase-3 was evident within neurons transporting gp120. These results indicate that axonal transport of gp120 might exacerbate the pathogenesis of HIV-1.
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Introduction
Neurological abnormalities occur in a significant number of human immunodeficiency virus (HIV)-infected individuals during the late phase of infection (Janssen et al., 1989) . Post mortem brains of these individuals have revealed neuronal loss, simplification of synaptic contacts, astrocytosis, and microglial nodules with multinucleated giant cells (Everall et al., 1993; Masliah et al., 1997) . These pathological alterations occur even though HIV-1 productively infects only macrophages and microglia (Budka et al., 1987; Eilbott et al., 1989) and astrocytes can support only limited viral replication (Tornatore et al., 1994) . Additionally, markers of neurodegeneration can frequently be detected in brain areas that are distant from sites of viral replication. Given the fact that HIV infection in the brain is relatively anatomically restricted, an unresolved issue is how low viral load in the brain can cause such widespread neuronal dysfunction.
Experimental evidence has shown that viral proteins such as gp120, the activator of HIV transcription Tat, and accessory proteins Nef and Vpr, can cause neuronal cell death in vitro as well as in vivo [reviewed in (Matarrese and Malorni, 2005) ]. With regards to gp120, chemokine receptors, especially CXCR4, have been proposed to mediate its neurotoxic effect (Hesselgesser et al., 1998; Kaul and Lipton, 1999; Meucci et al., 1998; Zheng et al., 1999) . Consequently, much effort has been directed toward characterizing CXCR4 signal transduction mechanisms responsible for gp120 toxicity. However, far less is known about the role of gp120 trafficking in light of recent studies showing that Tat and gp120 can migrate to different brain areas by axonal transport (Bachis et al., 2006; Bruce-Keller et al., 2003) . Intriguingly, Tat internalization and transport occur independently from a receptor-mediated mechanism, whereas gp120, at least the T-tropic strain, requires the chemokine receptor CXCR4 for internalization in neurons (Bachis et al., 2003) . Interestingly, compounds that prevent gp120 axonal transport also block gp120 neurotoxicity (Bachis et al., 2006) .
Axonal transport is a universal mechanism in the nervous system that allows neurons to communicate between distant sites. Molecules that are transported include endogenous proteins, such as neurotrophic factors. These proteins travel along axons to be transported both anterogradely from cell bodies to the terminals or retrogradely from terminals to the cell bodies. Neurodegeneration may occur if the axonal transport is impaired. Moreover, in infectious diseases, exogenous proteins also utilize axonal transport. These include the prion protein (Borchelt et al., 1994) 
